Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Arrowhead Pharmaceuticals Inc ARWR

Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3,... see more

Recent & Breaking News (NDAQ:ARWR)

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Business Wire February 24, 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Business Wire February 5, 2026

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Business Wire January 27, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Business Wire January 20, 2026

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Business Wire January 7, 2026

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Business Wire January 7, 2026

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Business Wire January 6, 2026

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Business Wire January 6, 2026

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO(TM) (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Business Wire January 5, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Business Wire December 23, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire December 15, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Business Wire December 8, 2025

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Business Wire December 2, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Business Wire December 1, 2025

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Business Wire November 25, 2025

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Business Wire November 24, 2025

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Business Wire November 18, 2025

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Business Wire November 6, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Business Wire November 4, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 28, 2025

Podcasts